PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-65.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-47.67%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
7.50%
Diluted share reduction more than 1.5x GNPX's 80.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.04%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19589.97%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
3Y OCF/share CAGR at 50-75% of GNPX's 96.26%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-19587.84%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-19245.92%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
62.10%
3Y net income/share CAGR 50-75% of GNPX's 96.48%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
30196.53%
Equity/share CAGR of 30196.53% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5954.03%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
827.17%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-14.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.86%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.